Skip to content

Smartphone-based transcutaneous electrical acupoint stimulation as adjunctive therapy for hypertension: a cluster randomized controlled trial

Smartphone-based transcutaneous electrical acupoint stimulation as adjunctive therapy for hypertension: a cluster randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039400
Enrollment
Unknown
Registered
2020-10-26
Start date
2020-11-10
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Office SBP from 140 to 159 mm Hg and/or DBP from 90 to 99 mm Hg for participants who did not take antihypertensive drugs previously, or Office SBP from 120 to 159 mm Hg and/or DBP from 80 to 99 mm Hg for participants who do not changing antihypertensive therapy at least 1 month; 2. Aged between 18 and 65 years (male or female); 3. Answering and completing the questionnaires; 4. Using smartphone; 5. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Other diseases that can affect the blood pressure, including but not limited to diseases of renal parenchyma, renal artery stenosis, obstructive sleep apnea syndrome, and primary hyperaldosteronism; 2. Receiving medicines that affect blood pressure except antihypertensive drugs in previous 1 month, including but not limited to glucocorticoids, central nervous system inhibitors; 3. Contraindications for the use of acupoint stimulators: wearing a pacemaker and other implanted medical devices; scars, bruises, scratches or inflammation on the skin of the acupoints; allergic to electrodes; 4. Uncontrolled diabetes (HbA1c >= 6.5%); 5. Drug or alcohol abuse; 6. Pregnant or breastfeeding; 7. Participated in other clinical trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
the change in office systolic blood pressure;

Secondary

MeasureTime frame
the change in office diastolic blood pressure;the proportion of patients with office BP < 140/90 mmHg;the number of antihypertensive drugs and the number of participants using antihypertensive drugs;Morisky medication adherence scale (MMAS-8);Body mass index;Waist circumference;International Physical Activity Questionnaire (IPAQ);12-Item Short-Form (SF-12);Blinding assessment of valuator;

Countries

China

Contacts

Public ContactCun-Zhi Liu

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

lcz_tg@126.com+86 10-53912201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026